心房颤动抗凝治疗中国专家共识

被引：92

作者：

孙艺红

郭艺芳

机构：

[1] 中华医学会心血管病学分会

[2] 中国老年学学会心脑血管病专业委员会

[3] 中国生物医学工程学心律分会

[4] 中华医学会心电生理和起搏分会

[5] 中国医师协会循证医学专业委员会

[6] 心律失常联盟(中国)

[7] 北京大学人民医院心脏中心

[8] 河北省人民医院

来源：

中华内科杂志 | 2012年 / 11期

关键词：

D O I：

暂无

中图分类号：

R541.75 [];

学科分类号：

1002 ; 100201 ;

摘要：

<正>心房颤动(房颤)是最常见的心律失常之一。根据2004年所发表的数据,我国30～85岁居民中房颤患病率为0.77%。血栓栓塞性并发症是房颤致死致残的主要原因,而卒中是最为常见的表现类型。在非瓣膜性房颤患者中,缺血性卒中的年发生率(约5%)是非房颤患者的2～7倍。预防卒中的新发与复发应成为房颤患者综合管理策略中的主要内容。越来越多的研究证实,对于发生卒中风险

引用

页码：916 / 921

共 10 条

[1] 中国心房颤动现状的流行病学研究 [J].

周自强 ;

胡大一 ;

陈捷 ;

张仁汉 ;

李奎宝 ;

赵秀丽 .

中华内科杂志, 2004, (07) :15-18

[2]

Dabigatran-Induced Gastrointestinal Bleeding in an Elderly Patient with Moderate Renal Impairment[J] . Maura K Wychowski,Peter A Kouides.Annals of Pharmacotherapy . 2012 (4)

[3]

Epidemiology, Risk Factors for Stroke, and Management of Atrial Fibrillation in China[J] . Dayi Hu,Yihong Sun.Journal of the American College of Cardiology . 2008 (10)

[4]

Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial[J] . Jonathan Mant,FD Richard Hobbs,Kate Fletcher,Andrea Roalfe,David Fitzmaurice,Gregory YH Lip,Ellen Murray.The Lancet . 2007 (9586)

[5]

Effect of Food, an Antacid, and the H2 Antagonist Ranitidine on the Absorption of BAY 59–7939 (Rivaroxaban), an Oral, Direct Factor Xa Inhibitor, in Healthy Subjects[J] . Dagmar Kubitza,Michael Becka,Michael Zuehlsdorf,Wolfgang Mueck.The Journal of Clinical Pharmacology . 2006 (5)

[6]

Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects[J] . Dagmar Kubitza,Michael Becka,Georg Wensing,Barbara Voith,Michael Zuehlsdorf.European Journal of Clinical Pharmacology . 2005 (12)

[7]

Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation[J] . Francisco Pérez-Gómez,Eduardo Alegría,Jesus Berjón,Jose A. Iriarte,Javier Zumalde,Antonio Salvador,Luis Mataix.Journal of the American College of Cardiology . 2004 (8)

[8]

New Anticoagulant Drugs[J] . Jeffrey I. Weitz,Jack Hirsh.Chest . 2001 (1)

[9]

Characterization of Different Subsets of Atrial Fibrillation in General Practice in France: The ALFA Study[J] . Samuel Levy,Martine Maarek,Philippe Coumel,Louis Guize,Jean Lekieffre,Jean-Louis Medvedowsky,Alain Sebaoun.Circulation . 1999 (23)

[10]

The natural history of atrial fibrillation: Incidence, risk factors, and prognosis in the manitoba follow-up study[J] . Andrew D. Krahn,Jure Manfreda,Robert B. Tate,Francis A.L. Mathewson,T. Edward Cuddy.The American Journal of Medicine . 1995 (5)

← 1 →